Intarcia Therapuetics has been backed by the Bill and Melinda Gates Foundation on a new technology that could prevent the spread of infection

HIV remains one of the world’s most dangerous diseases, and despite plenty of 21st century medical breakthroughs, we haven’t been able to effectively combat the STD beyond reducing its effects or taking preventative measures against it. Despite advancements in gene editing through the use of CRISPR/Cas9, and other such tools, we still haven’t reached a point where we can safely say that we’ve defeated the virus once and for all. In response to the growing body of actionable research surrounding the virus, the Bill and Melinda Gates Foundation has recently announced a $140 million USD investment in an Intarcia Therapuetics program working to develop an implant embedded beneath the skin which will work to administer steady streams of anti-HIV drugs to infected bodies over the course of six to 12 months.

$15 provides access to this article and every case-study, interview, and analysis piece that we publish for the next 30 days. Our Premium Subscription also provides access to a database of over 100,000 articles on innovation in brand, customer, and retail experience.
Already a subscriber? Log in.